{"id":556642,"date":"2026-06-03T12:30:00","date_gmt":"2026-06-03T10:30:00","guid":{"rendered":"https:\/\/medizinonline.com\/?p=556642"},"modified":"2026-06-03T13:06:57","modified_gmt":"2026-06-03T11:06:57","slug":"recurrence-after-btk-inhibition-prognostic-factors-and-treatment-options","status":"publish","type":"post","link":"https:\/\/medizinonline.com\/en\/recurrence-after-btk-inhibition-prognostic-factors-and-treatment-options\/","title":{"rendered":"Recurrence after BTK inhibition &#8211; prognostic factors and treatment options"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Mantle cell lymphoma (MCL) is a rare B-cell non-Hodgkin&#8217;s lymphoma with a markedly heterogeneous course. The spectrum ranges from indolent, slowly progressive forms to highly aggressive variants. Diagnosis and treatment remain challenging, as clinical presentation, molecular markers and treatment response vary greatly. New targeted therapies and international registry projects are increasingly improving the prognosis, even though MCL remains a complex disease.   <\/strong><\/p>\n\n<div class=\"pmpro\"><div class=\"pmpro_card pmpro_content_message\"><div class=\"pmpro_card_content\">Dieser Inhalt ist nur f\u00fcr Benutzer der Gruppe: Medizinische Fachperson zug\u00e4nglich <br \/><a href=\"https:\/\/medizinonline.com\/en\/my-account\/packages\/\">Jetzt beitreten<\/a><\/div><div class=\"pmpro_card_actions pmpro_font-medium\">Already a member? <a href=\"https:\/\/medizinonline.com\/en\/log-in\/?redirect_to=https%3A%2F%2Fmedizinonline.com%2Fen%2Frecurrence-after-btk-inhibition-prognostic-factors-and-treatment-options%2F\">Log in here<\/a><\/div><\/div><\/div>","protected":false},"excerpt":{"rendered":"<p>Mantle cell lymphoma (MCL) is a rare B-cell non-Hodgkin&#8217;s lymphoma with a markedly heterogeneous course. The spectrum ranges from indolent, slowly progressive forms to highly aggressive variants. Diagnosis and treatment&#8230;&hellip;... <\/p>\n<div class=\"pmpro\"><div class=\"pmpro_card pmpro_content_message\"><div class=\"pmpro_card_content\">Dieser Inhalt ist nur f\u00fcr Benutzer der Gruppe: Medizinische Fachperson zug\u00e4nglich <br \/><a href=\"https:\/\/medizinonline.com\/en\/my-account\/packages\/\">Jetzt beitreten<\/a><\/div><div class=\"pmpro_card_actions pmpro_font-medium\">Already a member? <a href=\"https:\/\/medizinonline.com\/en\/log-in\/?redirect_to=https%3A%2F%2Fmedizinonline.com%2Fen%2Frecurrence-after-btk-inhibition-prognostic-factors-and-treatment-options%2F\">Log in here<\/a><\/div><\/div><\/div>","protected":false},"author":7,"featured_media":556643,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"pmpro_default_level":"","cat_1_feature_home_top":false,"cat_2_editor_pick":false,"csco_eyebrow_text":"Mantle cell lymphoma","footnotes":""},"category":[11548,11508,11353,11370],"tags":[92357,92357,92360,92345,92364,92341,92365,92358,85926,92365,92344,92337,92347,92338,92343,92339,92359,46066,34676,92354,92363,92353,37035,92366,37054,92361,92346,92356,92362,92348,92340,92355,92355,92352,92350,92342,92349,92351,92351],"powerkit_post_featured":[],"class_list":["post-556642","post","type-post","status-publish","format-standard","has-post-thumbnail","category-rx-en","category-education","category-hematology","category-oncology","tag-acalabrutinib","tag-aggressive-mcl","tag-autologous-stem-cell-transplantation-mcl","tag-b-cell-non-hodgkins-lymphoma","tag-bcl2-blockade","tag-btk-inhibition","tag-btk-inhibitors-2","tag-btk-inhibitors","tag-cd20-antibody-therapy","tag-chemo-immunotherapy-mcl","tag-cyclin-d1-overexpression","tag-emcl-register","tag-glove-scheme","tag-glove-treatment-scheme","tag-heterogeneous-course-mcl","tag-histology","tag-ibrutinib-en","tag-immunophenotyping","tag-indolent-mcl","tag-ki-67-proliferation-index","tag-mantle-cell-lymphoma","tag-mantle-cell-lymphoma-2","tag-mcl-en","tag-mcl-diagnostics","tag-mcl-prognosis-factors","tag-mcl-recurrence","tag-mcl-therapy","tag-mipi-score","tag-pet-ct-mcl","tag-pirtobrutinib","tag-recurrence-after-btk-inhibition","tag-sox11-status","tag-t1114-translocation","tag-tp53-mutation-mcl","tag-zanubrutinib","pmpro-level-required","pmpro-level-1","pmpro-no-access"],"acf":[],"publishpress_future_action":{"enabled":false,"date":"2026-06-27 03:07:05","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category","extraData":[]},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"wpml_current_locale":"en_US","wpml_translations":{"fr_FR":{"locale":"fr_FR","id":556710,"slug":"recidive-apres-inhibition-de-btk-facteurs-pronostiques-et-options-therapeutiques","post_title":"R\u00e9cidive apr\u00e8s inhibition de BTK - facteurs pronostiques et options th\u00e9rapeutiques","href":"https:\/\/medizinonline.com\/fr\/recidive-apres-inhibition-de-btk-facteurs-pronostiques-et-options-therapeutiques\/"},"it_IT":{"locale":"it_IT","id":556707,"slug":"recidiva-dopo-linibizione-di-btk-fattori-prognostici-e-opzioni-di-trattamento","post_title":"Recidiva dopo l'inibizione di BTK - fattori prognostici e opzioni di trattamento","href":"https:\/\/medizinonline.com\/it\/recidiva-dopo-linibizione-di-btk-fattori-prognostici-e-opzioni-di-trattamento\/"},"pt_PT":{"locale":"pt_PT","id":556702,"slug":"recorrencia-apos-inibicao-da-btk-factores-de-prognostico-e-opcoes-de-tratamento","post_title":"Recorr\u00eancia ap\u00f3s inibi\u00e7\u00e3o da BTK - factores de progn\u00f3stico e op\u00e7\u00f5es de tratamento","href":"https:\/\/medizinonline.com\/pt-pt\/recorrencia-apos-inibicao-da-btk-factores-de-prognostico-e-opcoes-de-tratamento\/"},"es_ES":{"locale":"es_ES","id":556698,"slug":"recurrencia-tras-la-inhibicion-de-la-btk-factores-pronosticos-y-opciones-de-tratamiento","post_title":"Recurrencia tras la inhibici\u00f3n de la BTK: factores pron\u00f3sticos y opciones de tratamiento","href":"https:\/\/medizinonline.com\/es\/recurrencia-tras-la-inhibicion-de-la-btk-factores-pronosticos-y-opciones-de-tratamiento\/"}},"_links":{"self":[{"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/posts\/556642","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/comments?post=556642"}],"version-history":[{"count":1,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/posts\/556642\/revisions"}],"predecessor-version":[{"id":556644,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/posts\/556642\/revisions\/556644"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/media\/556643"}],"wp:attachment":[{"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/media?parent=556642"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/category?post=556642"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/tags?post=556642"},{"taxonomy":"powerkit_post_featured","embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/powerkit_post_featured?post=556642"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}